HazMat Fee + There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
| Type | HazMat fee for 500 gram (Estimated) |
| Excepted Quantity | USD 0.00 |
| Limited Quantity | USD 15-60 |
| Inaccessible (Haz class 6.1), Domestic | USD 80+ |
| Inaccessible (Haz class 6.1), International | USD 150+ |
| Accessible (Haz class 3, 4, 5 or 8), Domestic | USD 100+ |
| Accessible (Haz class 3, 4, 5 or 8), International | USD 200+ |


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | HD1 ↓ ↑ | HD2 ↓ ↑ | HDAC ↓ ↑ | HDAC1 ↓ ↑ | HDAC10 ↓ ↑ | HDAC11 ↓ ↑ | HDAC2 ↓ ↑ | HDAC3 ↓ ↑ | HDAC4 ↓ ↑ | HDAC5 ↓ ↑ | HDAC6 ↓ ↑ | HDAC7 ↓ ↑ | HDAC8 ↓ ↑ | HDAC9 ↓ ↑ | 其他靶点 | 纯度 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Givinostat HCl monohydrate |
++++
HD1-B, IC50: 7.5 nM HD1-A, IC50: 16 nM |
+++
HD2, IC50: 10 nM |
99%+ | ||||||||||||||||
| MC1568 |
++
HD1-A (Maize), IC50: 100 nM HD1-B (Maize), IC50: 3.4 μM |
96% | |||||||||||||||||
| Trichostatin A |
++++
HDAC, IC50: ~1.8 nM |
99%+ | |||||||||||||||||
| Scriptaid | ✔ | 99%+ | |||||||||||||||||
| Valproic acid sodium | ✔ | Autophagy | 97% | ||||||||||||||||
| AR-42 |
+++
HDAC, IC50: 30 nM |
99%+ | |||||||||||||||||
| Dacinostat |
+++
HDAC, IC50: 32 nM |
98+% | |||||||||||||||||
| CUDC-101 |
++++
HDAC, IC50: 4.4 nM |
++++
HDAC1, IC50: 4.5 nM |
+++
HDAC10, IC50: 26.1 nM |
+++
HDAC2, IC50: 12.6 nM |
++++
HDAC3, IC50: 9.1 nM |
+++
HDAC4, IC50: 13.2 nM |
+++
HDAC5, IC50: 11.4 nM |
++++
HDAC6, IC50: 5.1 nM |
+
HDAC7, IC50: 373 nM |
++
HDAC8, IC50: 79.8 nM |
++
HDAC9, IC50: 67.2 nM |
HER2,EGFR | 99%+ | ||||||
| M344 |
++
HDAC, IC50: 100 nM |
99%+ | |||||||||||||||||
| Splitomicin |
+
Sir2p, IC50: 60 μM |
99% | |||||||||||||||||
| Panobinostat |
++++
HDAC (MOLT-4 cells), IC50: 5 nM HDAC (Reh cells), IC50: 20 nM |
98% | |||||||||||||||||
| Sodium 4-Phenylbutyrate | ✔ | 98% | |||||||||||||||||
| Vorinostat |
+++
HDAC, IC50: ~10 nM |
98% | |||||||||||||||||
| Curcumin | ✔ | Nrf2,NF-κB | 98% | ||||||||||||||||
| Belinostat |
+++
HDAC, IC50: 27 nM |
98% | |||||||||||||||||
| RG-2833 |
++
HDAC1, Ki: 32 nM |
++
HDAC3, Ki: 5 nM |
98% | ||||||||||||||||
| Valproic acid |
+
HDAC1, IC50: 0.4 mM |
98% | |||||||||||||||||
| BG45 |
+
HDAC1, IC50: 2 μM |
+
HDAC2, IC50: 2.2 μM |
+
HDAC3, IC50: 289 nM |
99%+ | |||||||||||||||
| Entinostat |
+
HDAC1, IC50: 0.51 μM |
+
HDAC3, IC50: 1.7 μM |
98% | ||||||||||||||||
| Resminostat |
+++
HDAC1, IC50: 42.5 nM |
++
HDAC3, IC50: 50.1 nM |
++
HDAC6, IC50: 71.8 nM |
98+% | |||||||||||||||
| Romidepsin |
+++
HDAC1, IC50: 36 nM |
+++
HDAC2, IC50: 47 nM |
99%+ | ||||||||||||||||
| Parthenolide | ✔ | p53,NF-κB | 97% HPLC | ||||||||||||||||
| Tacedinaline |
+
HDAC1, IC50: 0.9 μM |
+
HDAC2, IC50: 0.9 μM |
+
HDAC3, IC50: 1.2 μM |
98% | |||||||||||||||
| Mocetinostat |
++
HDAC1, IC50: 0.15 μM |
+
HDAC11, IC50: 0.59 μM |
+
HDAC2, IC50: 0.29 μM |
+
HDAC3, IC50: 1.66 μM |
98% | ||||||||||||||
| WT-161 |
++++
HDAC1, IC50: 8.35 nM |
+++
HDAC2, IC50: 15.4 nM |
++++
HDAC6, IC50: 0.4 nM |
99%+ | |||||||||||||||
| Fimepinostat |
++++
HDAC1, IC50: 1.7 nM |
++++
HDAC10, IC50: 2.8 nM |
++++
HDAC11, IC50: 5.4 nM |
++++
HDAC2, IC50: 5.0 nM |
++++
HDAC3, IC50: 1.8 nM |
+++
HDAC6, IC50: 27 nM |
99%+ | ||||||||||||
| Tucidinostat |
++
HDAC1, IC50: 95 nM |
++
HDAC10, IC50: 78 nM |
++
HDAC2, IC50: 160 nM |
++
HDAC3, IC50: 67 nM |
99%+ | ||||||||||||||
| Santacruzamate A |
++++
HDAC2, IC50: 119 pM |
99%+ | |||||||||||||||||
| (E,E)-RGFP966 |
++
HDAC3, IC50: 80 nM |
99%+ | |||||||||||||||||
| LMK-235 |
+++
HDAC4, IC50: 11.9 nM |
++++
HDAC5, IC50: 4.2 nM |
99%+ | ||||||||||||||||
| Tasquinimod | ✔ | 99%+ | |||||||||||||||||
| CAY10603 |
++++
HDAC6, IC50: 2 pM |
98% | |||||||||||||||||
| Tubastatin A |
+++
HDAC6, IC50: 15 nM |
98% | |||||||||||||||||
| Tubacin |
++++
HDAC6, IC50: 4 nM |
99%+ | |||||||||||||||||
| ACY-738 |
++++
HDAC6, IC50: 1.7 nM |
99%+ | |||||||||||||||||
| Nexturastat A |
++++
HDAC6, IC50: 5 nM |
99%+ | |||||||||||||||||
| BRD73954 |
+++
HDAC6, IC50: 36 nM |
++
HDAC8, IC50: 120 nM |
99% | ||||||||||||||||
| Tubastatin A HCl |
+++
HDAC6, IC50: 15 nM |
+
HDAC8, IC50: 854 nM |
98% | ||||||||||||||||
| PCI-34051 |
+++
HDAC8, IC50: 10 nM |
99%+ | |||||||||||||||||
| Ricolinostat |
++
HDAC1, IC50: 58 nM |
++
HDAC2, IC50: 48 nM |
++
HDAC3, IC50: 51 nM |
++++
HDAC6, IC50: 4.7 nM |
++
HDAC8, IC50: 100 nM |
99%+ | |||||||||||||
| Droxinostat |
+
HDAC3, IC50: 16.9 μM |
+
HDAC6, IC50: 2.47 μM |
+
HDAC8, IC50: 1.46 μM |
99%+ | |||||||||||||||
| Abexinostat |
++++
HDAC1, Ki: 7 nM |
+++
HDAC10, IC50: 24 nM |
+++
HDAC2, Ki: 19 nM |
++++
HDAC3/SMRT, Ki: 8.2 nM |
+++
HDAC6, Ki: 17 nM |
+
HDAC8, IC50: 280 nM |
98%+ | ||||||||||||
| Citarinostat |
+++
HDAC1, IC50: 35 nM |
+++
HDAC2, IC50: 45 nM |
+++
HDAC3, IC50: 46 nM |
++++
HDAC6, IC50: 2.6 nM |
++
HDAC8, IC50: 137 nM |
99%+ | |||||||||||||
| HPOB |
+
HDAC1, IC50: 2.9 μM |
+
HDAC10, IC50: 3.0 μM |
+
HDAC2, IC50: 4.4 μM |
+
HDAC3, IC50: 1.7 μM |
++
HDAC6, IC50: 56 nM |
+
HDAC8, IC50: 2.8 μM |
97% | ||||||||||||
| Quisinostat 2HCl |
++++
HDAC1, IC50: 0.11 nM |
++++
HDAC10, IC50: 0.46 nM |
++++
HDAC11, IC50: 0.37 nM |
++++
HDAC2, IC50: 0.33 nM |
++++
HDAC3, IC50: 4.86 nM |
++++
HDAC4, IC50: 0.64 nM |
++++
HDAC5, IC50: 3.69 nM |
++++
HDAC8, IC50: 4.26 nM |
97% | ||||||||||
| Domatinostat |
+
HDAC1, IC50: 1.20 μM |
+
HDAC10, IC50: 21 μM |
+
HDAC11, IC50: 9.7 μM |
+
HDAC2, IC50: 1.12 μM |
+
HDAC3, IC50: 0.57 μM |
+
HDAC5, IC50: 11.3 μM |
+
HDAC9, IC50: 50 μM |
99%+ | |||||||||||
| TMP269 |
++
HDAC4, IC50: 157 nM |
++
HDAC5, IC50: 97 nM |
+++
HDAC7, IC50: 43 nM |
+++
HDAC9, IC50: 23 nM |
99%+ | ||||||||||||||
| Pracinostat |
++
HDAC1, IC50: 49 nM |
+++
HDAC10, IC50: 40 nM |
++
HDAC11, IC50: 93 nM |
++
HDAC2, IC50: 96 nM |
+++
HDAC3, IC50: 43 nM |
++
HDAC4, IC50: 56 nM |
+++
HDAC5, IC50: 47 nM |
+
HDAC6, IC50: 1.008 μM |
++
HDAC7, IC50: 137 nM |
++
HDAC8, IC50: 140 nM |
++
HDAC9, IC50: 70 nM |
99%+ | |||||||
| TMP195 |
++
HDAC4, Ki: 59 nM |
++
HDAC5, Ki: 60 nM |
+++
HDAC7, Ki: 26 nM |
+++
HDAC9, Ki: 15 nM |
99%+ | ||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 描述 | HDAC6 (histone deacetylase 6) is a structurally and functionally unique class Iib isoform localized almost exclusively to the cytoplasm. HDAC6 loss of function results in an antidepressant-like phenotype. ACE-775 is a potent and selective HDAC6 inhibitor with an IC50 value of 7.5 nM. In RN46A-B14 cells treated with ACY-775 (2.5 μM) for 4 hours, there was an increase in the acetylated (lysine 40) fraction of α-tubulin. ACY-775 rapidly distribute to the brain leading to a total drug exposure in CNS comparable to that of peripheral tissues. In wild-type mice, ACY-775 (50 mg/kg; 24 h, 4 h, and 30 min) caused significant increases in α-tubulin acetylation in all tested brain regions: cortex, hippocampus and cerebellum and stimulated mouse exploratory behaviors in novel environments[3]. |
| 作用机制 | Activity of ACY-775 is fully explained by inhibition of the C terminal catalytic domain of HDAC6[3]. |
| Concentration | Treated Time | Description | References | |
| RN46A-B14 cells | 2.5 μM | 4 h | To evaluate the inhibitory effect of ACY-775 on HDAC6 and its impact on α-tubulin acetylation. Results showed that ACY-775 significantly increased the acetylation of α-tubulin but had no significant effect on histone H3K9 acetylation. | Neuropsychopharmacology. 2014 Jan;39(2):389-400. |
| Dorsal root ganglion (DRG) neurons | 2.5 μM | Overnight | To evaluate the ability of ACY-738 and ACY-775 to restore mitochondrial axonal transport defects. Results showed that both inhibitors significantly increased mitochondrial motility and total number, and significantly enhanced the number of retrogradely transported mitochondria. | Neurotherapeutics. 2017 Apr;14(2):417-428. |
| Mouse neuroblastoma (N2a) cells | 1 μM | Overnight | To assess the effect of ACY-738 and ACY-775 on the acetylation status of α-tubulin and histone 3. Results showed that both inhibitors significantly enhanced α-tubulin acetylation at 1 μM concentration, while histone acetylation remained unaffected. | Neurotherapeutics. 2017 Apr;14(2):417-428. |
| Administration | Dosage | Frequency | Description | References | ||
| Mice | NIH Swiss mice | Intraperitoneal injection | 50 mg/kg | Single administration | To evaluate the antidepressant-like effects of ACY-775 in vivo. Results showed that ACY-775 significantly reduced immobility time in the tail suspension test, demonstrating antidepressant-like effects. Additionally, ACY-775 increased α-tubulin acetylation levels in the brain. | Neuropsychopharmacology. 2014 Jan;39(2):389-400. |
| Mice | HSPB1 S135F-induced CMT2 mouse model | Intraperitoneal injection | 3 mg/kg | Once daily for 21 days | To evaluate the effect of ACY-775 on reversing motor and sensory deficits in the CMT2 mouse model. Results showed that ACY-775 significantly improved motor and sensory nerve action potential amplitudes and increased reinnervation of neuromuscular junctions. | Neurotherapeutics. 2017 Apr;14(2):417-428. |
| Macaque | Macaque model | Intravenous injection | 0.1 and 2 mg/kg | Single dose, lasting 120 minutes | Compare HDAC6 target occupancy between EKZ-317 and ACY-775, showing that EKZ-317 achieved high occupancy (≥90%) at both 0.1 and 2 mg/kg doses, while ACY-775 only achieved similar occupancy at 2 mg/kg dose | ACS Chem Neurosci. 2020 Apr 1;11(7):1093-1101 |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
3.03mL 0.61mL 0.30mL |
15.14mL 3.03mL 1.51mL |
30.27mL 6.05mL 3.03mL |
|
| CAS号 | 1375466-18-4 |
| 分子式 | C17H19FN4O2 |
| 分子量 | 330.36 |
| SMILES Code | O=C(C1=CN=C(NC2(C3=CC=CC(F)=C3)CCCCC2)N=C1)NO |
| MDL No. | MFCD30533691 |
| 别名 | |
| 运输 | 蓝冰 |
| InChI Key | IYBURCQQEUNLDL-UHFFFAOYSA-N |
| Pubchem ID | 57382288 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place, sealed in dry, 2-8°C |
| 溶解方案 |
DMSO: 25 mg/mL(75.68 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1